A Phase I Dose Escalation Study of Daily x 3 Intravenous SJG-136 in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of Daily x 3 Intravenous SJG-136 in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2014

At a glance

  • Drugs SG 2000 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2009 Planned end date changed from 1 Sep 2006 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 02 Jun 2008 Final results presented at the American Society of Clinical Oncology (ASCO) 2008.
    • 02 Jun 2008 Status changed from in progress to completed as reported in an Ipsen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top